Atrium Therapeutics, Inc. (RNA) Revenue History
Annual and quarterly revenue from 2018 to present
RNA Revenue Over Time (2018–2025)
RNA Revenue Growth History
6 of 7 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +511.9%
- FY2020 revenue growth
- +192.7%
- FY2021 revenue growth
- +37.4%
- FY2022 revenue growth
- -1.1%
- FY2023 revenue growth
- +3.6%
- FY2024 revenue growth
- +14.0%
- FY2025 revenue growth
- +70.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $19.6M | +1148.3% |
| Q4 2025 | $859K | -71.1% |
| Q3 2025 | $12.5M | +434.0% |
| Q2 2025 | $3.8M | +88.1% |
| Q1 2025 | $1.6M | -55.6% |
| Q4 2024 | $3.0M | +35.6% |
| Q3 2024 | $2.3M | -17.1% |
| Q2 2024 | $2.0M | -11.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
RNA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RNA Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 16, 2026, Atrium Therapeutics, Inc. (RNA) generated trailing twelve-month (TTM) revenue of $36.8 million, reflecting explosive growth of +1148.3% year-over-year. The most recent quarter (Q1 2026) recorded $19.6 million in revenue, up 2185.8% sequentially.
Historical Growth Trajectory
RNA's 5-year compound annual growth rate (CAGR) stands at +22.4%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +26.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Atrium Therapeutics, Inc.'s highest annual revenue of $18.6 million was recorded in 2025, an all-time high.
Revenue by Segment
RNA's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including SRPT (-2.2% YoY), MDWD (-24.6% YoY), and FOLD (+20.0% YoY) — RNA has outperformed the peer group in revenue growth. Compare RNA vs SRPT →
RNA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 RNACurrent | $37M | +1148.3% | +22.4% | -412.6% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 MDWD | $17M | -24.6% | -4.9% | -149.1% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% |
RNA Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $18.6M | +70.9% | $18.6M | 100.0% | $-76,814,000 | -412.6% |
| 2024 | $10.9M | +14.0% | $10.9M | 100.0% | $-378,936,000 | -3477.4% |
| 2023 | $9.6M | +3.6% | $7.5M | 78.0% | $-235,598,000 | -2464.4% |
| 2022 | $9.2M | -1.1% | $7.8M | 85.0% | $-178,913,000 | -1939.6% |
| 2021 | $9.3M | +37.4% | $-91,856,000 | -984.9% | $-118,051,000 | -1265.8% |
| 2020 | $6.8M | +192.7% | $-30,815,000 | -454.0% | $-44,277,000 | -652.4% |
| 2019 | $2.3M | +511.9% | $2.3M | 100.0% | $-17,332,000 | -747.4% |
| 2018 | $379K | - | $-8,057,000 | -2125.9% | $-10,498,000 | -2769.9% |
What if you invested $1,000 in RNA back in 2018?
Total return with dividends reinvested · 8+ years of data
Calculate ReturnsHow much would $100/month in RNA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs RNA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationRNA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowRNA — Frequently Asked Questions
Quick answers to the most common questions about buying RNA stock.
Is RNA's revenue growth accelerating or slowing?
RNA revenue growth is accelerating. TTM revenue reached $37M, up +1148.3% year-over-year — ahead of the 5-year CAGR of +22.4%. This indicates the business is expanding faster than its historical baseline.
What is RNA's revenue history from 2018 to 2026?
Atrium Therapeutics, Inc. (RNA) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $37M, growing at +1148.3% YoY. The 5-year CAGR is +22.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RNA's long-term revenue growth rate (CAGR)?
Atrium Therapeutics, Inc.'s 5-year revenue CAGR of +22.4% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +1148.3% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RNA.
Why does RNA's quarterly revenue fluctuate?
RNA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Atrium Therapeutics, Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is RNA's revenue distributed by segment?
RNA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RNA's revenue compare to industry peers?
Atrium Therapeutics, Inc. (RNA) with TTM revenue of $37M and +1148.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.